BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Pevion Biotech Ltd. Appoints New CEO


1/12/2009 7:35:40 AM

Ittigen, January 12, 2009 - Pevion Biotech today announces the appointment of Dr. Thomas P. Stauffer to the position of Chief Executive Officer of the company, effective January 1, 2009, succeeding Peter Klein. Prior to his appointment Dr. Stauffer served as COO of Pevion Biotech. In this function he managed the financial, intellectual property and legal issues of the company. Before joining the company, Dr. Thomas Stauffer served as an IP consultant for small and midsize biotechnology companies and built and managed a department for IP services at the Swiss Federal Institute of Intellectual Property. Dr. Stauffer holds a PhD from the Swiss Federal Institute of Technology and an MSc from the University of Zurich.

Dr. Peter Grogg, chairman of the company, stated: "Dr. Stauffer knows the vaccine field very well and has proven himself in the company. Therefore the Board of Pevion Biotech is firmly convinced that Dr. Stauffer will be able to move the company forward and advance the clinical development of Pevion Biotech's vaccine candidates, thus generating economic value.”

About Pevion Biotech Pevion Biotech is a privately owned Swiss biopharmaceutical company focusing on the preclinical and clinical development of vaccines to prevent/treat infectious diseases and cancer. For its vaccine development, the company uses its virosome-based technology which is already validated by two registered and marketed vaccines. The combination of this virosome technology with novel innovative antigens substantially reduces the known risk in biotechnological development and permits the targeting of diseases where so far no appropriate treatment is available. Pevion Biotech targets indications which represent major medical needs, including prophylactic or therapeutic vaccines against breast cancer, candidiasis, RSV and influenza. One virosome-based vaccine candidate is currently in clinical development. For further questions, please contact: Miriam Peters Tel: +41 31 550 44 01 miriam.peters@pevion.com www.pevion.com

Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES